Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

TVTX - Travere Therapeutics, Inc. So'nggi... | Finranks

Home

TVTX

T

Travere Therapeutics, Inc. (TVTX)

NGM – Real vaqt narxi. Valyuta: USD

27.25

-0.67 (-2.40%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

27.36

+0.11 (0.40%)

Bozordan keyin: Mar 27, 2026, 7:18 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms

Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms

Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost discipline.

Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript

Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say

Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates

Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates

Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago.

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of meaningful advancement for Travere, strengthening both our commercial execution and long-term growth outlook,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “In IgA nephropathy, continued adoption of FILSPARI underscores its foundational positioning and the posi.

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-.

Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?

Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videolar

No Data

There is no data to display

Press-relizlar

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of meaningful advancement for Travere, strengthening both our commercial execution and long-term growth outlook,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “In IgA nephropathy, continued adoption of FILSPARI underscores its foundational positioning and the posi.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 49,200 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted.

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.

TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.